The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease

Research output: Contribution to journalArticle

2 Citations (Scopus)
Original languageEnglish
Pages (from-to)22-23
Number of pages2
JournalThe Lancet Neurology
Volume8
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Galantamine
Nootropic Agents
Activities of Daily Living
Alzheimer Disease
Safety

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease. / Farlow, Martin.

In: The Lancet Neurology, Vol. 8, No. 1, 01.2009, p. 22-23.

Research output: Contribution to journalArticle

@article{7525d51ac70342d6bafca83f9d459dee,
title = "The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease",
author = "Martin Farlow",
year = "2009",
month = "1",
doi = "10.1016/S1474-4422(08)70262-X",
language = "English",
volume = "8",
pages = "22--23",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease

AU - Farlow, Martin

PY - 2009/1

Y1 - 2009/1

UR - http://www.scopus.com/inward/record.url?scp=57149088615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149088615&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(08)70262-X

DO - 10.1016/S1474-4422(08)70262-X

M3 - Article

C2 - 19042160

AN - SCOPUS:57149088615

VL - 8

SP - 22

EP - 23

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 1

ER -